Status note All oncology clinical development discontinued; clinical trial activities ceased September 2024; preclinical work in non-oncology indications commenced Q2 FY2026.
Partnerships Kyowa Kirin (license terminated 2023)
Indications
indolent B-cell lymphomas(Phase 2)
Status note Development discontinued November 2022 after FDA feedback on Phase 3 COASTAL design; assessing out-licensing or sale opportunities.
Per-asset detail extracted from the 10-Q filed 2026-05-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
67,292
no change
0.00%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.